ORA measurements show good short-term repeatability in normal volunteers. Thus, this device appears to be applicable in clinical practice.

Once diagnosed, the glaucoma patient requires lifelong treatment, usually with topical IOP lowering medication. The aim of glaucoma treatment is to reduce IOP, a ‘clinician‐based’ measure, and thus treatment has no obvious effect on the patient’s vision or their ability to carry out every‐day tasks. There is evidence to suggest that medication underuse occurs in patients with glaucoma. Deliberate medication underuse occurs when the patient is concerned with aspects relating to either the treatment safety, or treatment efficacy and necessity. In glaucoma, medication misuse may lead to inappropriate conclusions regarding treatment inefficacy, resulting in unnecessary changes and additions to treatment, and, more seriously, avoidable, irreversible visual loss. Improving patient adherence to their treatment is a complex issue influenced by a number of factors. This talk will explore some of the issues regarding glaucoma medication misuse and the role of the 'doctor‐patient' relationship in promoting adherence to treatment.

Purpose Title: Corneal biomechanics and glaucoma risk‐ where are we now? Methods The impact of central corneal thickness (CCT) on intraocular pressure (IOP) measurement accuracy has been well documented, and CCT has become part of the routine work up of a glaucoma suspect patient. What is relatively unclear is whether corneal properties, such as CCT and in vivo measures of corneal biomechanics, give an indication of the risk of glaucoma susceptibility. This talk will consider whether there is a role for the cornea that lies beyond the limits of IOP measurement accuracy, discussing the evidence as to whether current measures of corneal biomechanics may be used as a surrogate marker of optic nerve compliance.